Angiotensin-converting enzyme inhibitors (ACEIs) are considered as primary drugs for the secondary prevention of myocardial infarction (MI), and angiotensin receptor blockers (ARBs) are used when ACEIs are not tolerated [1, 2]. The gene discussed is ACE; the disease is myocardial infarction.